Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 DONGZhi-qiang ¹ , LIXue-yan ¹ , WANGZhong-chen ² , LIXi-chun ³ , LIZheng-mao ⁴

1. Department of Vascular Surgery, Daqing Oilfield General Hospital, Daqing 163000, Heilongjiang Province, China;
2. Department of Vascular Surgery, Daqing Longnan Hospital, Daqing 163000, Heilongjiang Province, China;
3. Department of Vascular Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China;
4. Department of Vascular Surgery, The First People's Hospital of Qiqihar City, Qiqihar 161000, Heilongjiang Province, China;

Corresponding?author：

DONGZhi-qiang, Email: dzq431978@163.com

Keywords：

Sarpogrelate hydrochloride; Femoral artery; Stent implantation; Restenosis; Prevention

DOI：

10.7507/1007-9424.20140172

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the clinical efficacy of sarpogrelate hydrochloride in preventing restenosis after femoral artery stent implantation. Methods Two hundreds and fifty-one cases of ischemic disease of lower extremity (286 affected limbs in total) who got treatment in our hospital were collected, and were divided into prevention group(125 cases with 146 affected limbs) and control group(126 cases with 140 affected limbs) according kinds of medicine. At the basement of medicine in control group, cases of prevention group got treatment of sarpogrelate hydrochloride in addition. Comparison of related indexed was performed by SPSS 17.0 software. Results Compared with before treatment in prevention group, only foot skin ulcer and gangrene score decreased(P<0.05), and there were no significant difference on other indexes included visual anafogue scales(VAS), intermittent claudication distance score, ankle brachial index (ABI), and vascular stenosis score(P>0.05). But in control group, compared with before treatment, foot skin ulcer and gangrene score and ABI value decreased(P<0.05), the VAS score, intermittent claudication distance score, and vascular stenosis score increased(P<0.05). There were significant difference on the difference between after treatment and before treatment of all 5 indexes(P<0.05), that the changed value of foot skin ulcer and gangrene score was higher in prevention group, but lower on other 4 indexes. There were no untoward effect happened during treatment. Conclusion Clinical effect of sarpogrelate hydrochloride in the prevention of restenosis of the femoral artery after stent implantation was significantly, and it can keep related indexes stable.

Citation： DONGZhi-qiang, LIXue-yan, WANGZhong-chen, LIXi-chun, LIZheng-mao. Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(6): 727-730. doi: 10.7507/1007-9424.20140172 Copy

1.	?馬震寰,楊鏞,楊國凱,等.下肢動脈硬化閉塞癥繼發血栓形成治療分析[J].中國普外基礎與臨床雜志, 2010, 17(3):275-277.
2.	王玉琦,史振宇.我國血管外科的現狀與展望[J].中國普外基礎與臨床雜志, 2008, 15(6):387-389.
3.	Takasawa Y, Iijima R, Shiba M, et al.Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention[J].J Cardiol, 2010, 55(3):391-396.
4.	Norgren L, Hiatt WR, Dormandy JA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ)[J].J Vasc Surg, 2007, 45 Suppl S:S5-S67.
5.	葉任高,陸再英.內科學[M].第6版.北京:人民衛生出版社, 2006:161-176.
6.	吳在德,吳肇漢.外科學[M].第6版.北京:人民衛生出版社, 2008:129-130.
7.	Edmonds ME, Foster AVM, Sanders LJ著.于德民,王鵬華譯.糖尿病足診治實踐彩色圖解[M].天津:天津科技翻譯出版公司, 2006:14-16.
8.	Tuttle KR.Linking metalism and immunology:diabetic nephropathy is anin flammatorydisease[J].J Am Soe Nephrol, 2005, 16(6):1537-1538.
9.	張旭,呂豪,孫振學.銀杏達莫聯合前列腺素E1治療糖尿病并發外周動脈疾病的臨床研究[J].中國基層醫藥, 2010, 17(z2):81-82.
10.	Kroeze WK, Kristiansen K, Roth BL.Molecular biology of serotonin receptors structure and function at the molecular level[J].Curr Top Med Chem, 2002, 2(6):507-528.
11.	陳潔,葉志東,樊雪強,等.鹽酸沙格雷酯用于股腘動脈長段閉塞介入治療效果及安全性分析[J].心肺血管病雜志, 2013, 32(1):7-9.
12.	邵壯,顧洪斌,王志鴻,等.鹽酸沙格雷酯對糖尿病伴膝下動脈病變球囊擴張成形術后療效的影響[J].心肺血管病雜志, 2013, 32(1):16-19.

1. ?馬震寰,楊鏞,楊國凱,等.下肢動脈硬化閉塞癥繼發血栓形成治療分析[J].中國普外基礎與臨床雜志, 2010, 17(3):275-277.
2. 王玉琦,史振宇.我國血管外科的現狀與展望[J].中國普外基礎與臨床雜志, 2008, 15(6):387-389.
3. Takasawa Y, Iijima R, Shiba M, et al.Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention[J].J Cardiol, 2010, 55(3):391-396.
4. Norgren L, Hiatt WR, Dormandy JA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ)[J].J Vasc Surg, 2007, 45 Suppl S:S5-S67.
5. 葉任高,陸再英.內科學[M].第6版.北京:人民衛生出版社, 2006:161-176.
6. 吳在德,吳肇漢.外科學[M].第6版.北京:人民衛生出版社, 2008:129-130.
7. Edmonds ME, Foster AVM, Sanders LJ著.于德民,王鵬華譯.糖尿病足診治實踐彩色圖解[M].天津:天津科技翻譯出版公司, 2006:14-16.
8. Tuttle KR.Linking metalism and immunology:diabetic nephropathy is anin flammatorydisease[J].J Am Soe Nephrol, 2005, 16(6):1537-1538.
9. 張旭,呂豪,孫振學.銀杏達莫聯合前列腺素E1治療糖尿病并發外周動脈疾病的臨床研究[J].中國基層醫藥, 2010, 17(z2):81-82.
10. Kroeze WK, Kristiansen K, Roth BL.Molecular biology of serotonin receptors structure and function at the molecular level[J].Curr Top Med Chem, 2002, 2(6):507-528.
11. 陳潔,葉志東,樊雪強,等.鹽酸沙格雷酯用于股腘動脈長段閉塞介入治療效果及安全性分析[J].心肺血管病雜志, 2013, 32(1):7-9.
12. 邵壯,顧洪斌,王志鴻,等.鹽酸沙格雷酯對糖尿病伴膝下動脈病變球囊擴張成形術后療效的影響[J].心肺血管病雜志, 2013, 32(1):16-19.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Efficacy of Sarpogrelate Hydrochloride in Preventing Restenosis after Femoral Artery Stent Implantation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content